Anti-aging Gene Klotho: A Novel Therapeutic Target for Calcific Aortic Valve Dise

抗衰老基因Klotho:钙化性主动脉瓣疾病的新治疗靶点

基本信息

  • 批准号:
    8814275
  • 负责人:
  • 金额:
    $ 36.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-03-01 至 2018-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The mounting prevalence of risk factors such as aging, diabetes, and hypertension, coupled with genetic factors can perturb the cellular and molecular mechanism of the aortic valves leading to calcific aortic valve disease (CAVD) and ultimately aortic stenosis. Surgical replacement of the aortic valve remains the only and the last choice for the disease. Over 30,000 aortic valves were replaced in 2009. Patients with severe aortic stenosis who do not receive surgical valve replacement have a mortality rate of 37% at one year after symptom onset. However, replacement valves are susceptible to failure, necessitating additional surgeries. There currently is no effective medical therapy for CAVD due to the unknown etiology of the disease. Therefore, a conceptual breakthrough to develop novel targets and strategies to develop a cure for CAVD is paramount. Klotho is a recently-discovered anti- aging gene and is predominately expressed in kidneys. Klotho is a secreted protein. The level of circulating klotho declines in the aged population while the prevalence of CAVD increases in the aged population. The objective of this application is to determine, in animal models, if klotho deficiency is a causal factor of CAVD and if klotho gene delivery or klotho protein supplement could serve as an effective therapeutic strategy for CAVD. We will accomplish this objective by pursuing the following two complement specific aims. (1) Determine if klotho deficiency causes CAVD and investigate its molecular mechanism. (2) Investigate the hypothesis that in vivo klotho gene or protein delivery will attenuate or reverse CAVD in senescence-accelerated mice. The proposed work is innovative and significant because it utilizes state-of-the-art approaches to address CAVD which affects a large aged population but remains poorly explored. The results will reveal a novel etiological factor for senescence-related CAVD. The proposed research will provide important insights into therapeutic strategies for CAVD.
描述(由申请人提供):风险因素(如衰老、糖尿病和高血压)的发病率不断增加,加上遗传因素,可干扰主动脉瓣的细胞和分子机制,导致钙化性主动脉瓣疾病(CAVD),最终导致主动脉瓣狭窄。主动脉瓣置换术仍是治疗该病的唯一和最后选择。2009年更换了30 000多个主动脉瓣。没有接受外科瓣膜置换术的严重主动脉瓣狭窄患者在症状发作后一年的死亡率为37%。然而,置换瓣膜容易失效,需要额外的手术。由于CAVD的病因不明,目前尚无有效的药物治疗方法。因此,开发新的靶点和策略以开发CAVD的治愈方法的概念突破至关重要。Klotho是最近发现的抗衰老基因,主要在肾脏中表达。Klotho是一种分泌蛋白。老年人群中循环klotho水平下降,而老年人群中CAVD的患病率增加。本申请的目的是在动物模型中确定klotho缺乏是否是CAVD的致病因素,以及klotho基因递送或klotho蛋白补充剂是否可以作为CAVD的有效治疗策略。我们将通过以下两个相辅相成的具体目标来实现这一目标。(1)确定klotho缺乏是否导致CAVD并研究其分子机制。(2)研究体内klotho基因或蛋白质递送将减弱或逆转加速衰老小鼠中的CAVD的假设。拟议的工作是创新的和重要的,因为它利用最先进的方法来解决CAVD影响了大量的老年人口,但仍然很少探索。这些结果将揭示衰老相关CAVD的新病因。拟议的研究将为CAVD的治疗策略提供重要的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhongjie Sun其他文献

Zhongjie Sun的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhongjie Sun', 18)}}的其他基金

Investigation into Arterial Stiffness and Hypertension
动脉僵硬和高血压的调查
  • 批准号:
    10463821
  • 财政年份:
    2020
  • 资助金额:
    $ 36.45万
  • 项目类别:
Investigation into Arterial Stiffness and Hypertension
动脉僵硬和高血压的调查
  • 批准号:
    10053836
  • 财政年份:
    2020
  • 资助金额:
    $ 36.45万
  • 项目类别:
Investigation into Arterial Stiffness and Hypertension
动脉僵硬和高血压的调查
  • 批准号:
    10678777
  • 财政年份:
    2020
  • 资助金额:
    $ 36.45万
  • 项目类别:
Investigation into Arterial Stiffness and Hypertension
动脉僵硬和高血压的调查
  • 批准号:
    10251335
  • 财政年份:
    2020
  • 资助金额:
    $ 36.45万
  • 项目类别:
Epigenetic Regulation of Kidney Function and Blood Pressure
肾功能和血压的表观遗传调节
  • 批准号:
    10361558
  • 财政年份:
    2019
  • 资助金额:
    $ 36.45万
  • 项目类别:
Epigenetic Regulation of Kidney Function and Blood Pressure
肾功能和血压的表观遗传调控
  • 批准号:
    10113501
  • 财政年份:
    2019
  • 资助金额:
    $ 36.45万
  • 项目类别:
Epigenetic Regulation of Kidney Function and Blood Pressure
肾功能和血压的表观遗传调节
  • 批准号:
    9916697
  • 财政年份:
    2019
  • 资助金额:
    $ 36.45万
  • 项目类别:
Epigenetic Regulation of Kidney Function and Blood Pressure
肾功能和血压的表观遗传调控
  • 批准号:
    10579236
  • 财政年份:
    2019
  • 资助金额:
    $ 36.45万
  • 项目类别:
Epigenetic Regulation of Kidney Function and Blood Pressure
肾功能和血压的表观遗传调节
  • 批准号:
    9765836
  • 财政年份:
    2019
  • 资助金额:
    $ 36.45万
  • 项目类别:
Pilot Project Program
试点项目计划
  • 批准号:
    10219296
  • 财政年份:
    2017
  • 资助金额:
    $ 36.45万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.45万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了